World Drug and Medication: Clostridium Infections – Pipeline Review, H1 2012

• Publication date: February 2013
• Report size: 134 pages

This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. 'Clostridium Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University...

This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. 'Clostridium Infections - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Clostridium Infections.
- A review of the Clostridium Infections products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Clostridium Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Clostridium Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Clostridium Infections pipeline depth and focus of Clostridium Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Pathology Industry

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Clostridium Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Clostridium Infections 9
Clostridium Infections Therapeutics under Development by Firms 11
Clostridium Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Clostridium Infections Therapeutics – Products under Development by Firms 20
Clostridium Infections Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Clostridium Infections Therapeutics Development 24
Sanofi-Aventis 24
GlaxoSmithKline plc 25
Merck & Co., Inc. 26
Cangene Corporation 27
Takeda Pharmaceutical Firms Limited 28
Nanotherapeutics, Inc. 29
Actelion Ltd 30
Cubist Pharmaceuticals, Inc. 31
Mitsubishi Tanabe Pharma Corporation 32
ViroPharma Incorporated 33
Progenics Pharmaceuticals, Inc. 34
Avexa Limited 35
Optimer Pharmaceuticals, Inc. 36
Paratek Pharmaceuticals, Inc. 37
Intercell AG 38
AVANIR Pharmaceuticals 39
Oragenics, Inc. 40
XOMA Ltd. 41
Immuron Limited 42
Lipoxen PLC 43
Green Cross Corporation 44
LG Life Sciences, Ltd 45
Panacea Biotec Limited 46
Summit Corporation plc 47
PolyMedix, Inc. 48
e-Therapeutics plc 49
ActogeniX NV 50
November acta Biosystems Limited 51
Osel Inc. 52
iBio, Inc. 53
DynPort Vaccine Firms LLC 54
Molecular Targeting Technologies, Inc. 55
Clostridium Infections – Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
CB-183,315 - Drug Profile 62
Xenerex - Drug Profile 63
Dificid - Drug Profile 64
ACAM-CDIFF - Drug Profile 67
MU1140 - Drug Profile 68
AVX13616 - Drug Profile 69
Rifalazil - Drug Profile 70
Oritavancin - Drug Profile 72
LipoTet - Drug Profile 74
ETX1153c - Drug Profile 75
NVB302 - Drug Profile 76
MK-3415A - Drug Profile 77
XOMA 3AB - Drug Profile 78
SMT 19969 - Drug Profile 79
PMX-30016 - Drug Profile 80
Ramoplanin - Drug Profile 81
GSK 792014 + Infanrix + Pediarix - Drug Profile 82
V501 + Menactra + Adacel - Drug Profile 84
TdaP Vaccine - Drug Profile 86
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 87
Actacel - Drug Profile 89
DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile 90
Heptavalent Combination Vaccine - Drug Profile 92
Tdap - Drug Profile 93
VP 20621 - Drug Profile 94
MIYA-BM - Drug Profile 96
Botulism Antitoxin Heptavalent - Drug Profile 97
GSK217744 Formulation B - Drug Profile 99
GSK217744 Formulation A - Drug Profile 101
Tetracyclins For Clostridium - Drug Profile 103
Hexaxim - Drug Profile 104
Quadracel - Drug Profile 105
Clostridium Difficile Antibodies - Drug Profile 106
Cadazolid - Drug Profile 107
IC84 - Drug Profile 108
DtwP-HB-Hib (Recon) Vaccine - Drug Profile 110
Tetanus Toxin Monoclonal Antibody - Drug Profile 111
rBV A/B - Drug Profile 112
BK-4SP - Drug Profile 114
V419 + Pentacel + Prevnar 13 + RotaTeq - Drug Profile 115
C.Difficile Holotoxins + Alum Adjuvant - Drug Profile 117
Chimera Toxins + Alum Adjuvant - Drug Profile 118
V419 + Daptacel + PedvaxHIB + Prevnar 13 + RotaTeq - Drug Profile 120
GC1107 - Drug Profile 122
My Five - Drug Profile 123
IMM 308 - Drug Profile 125
KD-332 - Drug Profile 126
Easysix - Drug Profile 127
MGB-BP-3 - Drug Profile 129
TAK-361S - Drug Profile 130
SMT21829 - Drug Profile 131
Botulinum Toxin Vaccine - Drug Profile 132
ActoBiotic For Clostridium Difficile Enteropathy - Drug Profile 133
Clostridium Infections Therapeutics – Drug Profile Updates 134
Clostridium Infections Therapeutics – Discontinued Products 145
Clostridium Infections Therapeutics - Dormant Products 146
Clostridium Infections – Product Development Milestones 148
Featured News & Press Releases 148
Appendix 157
Methodology 157
Expert Panel Validation 158
Contact Us 158
Disclaimer 158

List of Tables

Number of Products Under Development for Clostridium Infections, H1 2012 13
Products under Development for Clostridium Infections – Comparative Analysis, H1 2012 14
Number of Products under Development by Firms, H1 2012 16
Number of Products under Development by Firms, H1 2012 (Contd..1) 17
Number of Products under Development by Firms, H1 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 19
Comparative Analysis by Late Stage Development, H1 2012 20
Comparative Analysis by Mid Clinical Stage Development, H1 2012 21
Comparative Analysis by Early Clinical Stage Development, H1 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 23
Products under Development by Firms, H1 2012 24
Products under Development by Firms, H1 2012 (Contd..1) 25
Products under Development by Firms, H1 2012 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2012 27
Sanofi-Aventis, H1 2012 28
GlaxoSmithKline plc, H1 2012 29
Merck & Co., Inc., H1 2012 30
Cangene Corporation, H1 2012 31
Takeda Pharmaceutical Firms Limited, H1 2012 32
Nanotherapeutics, Inc., H1 2012 33
Actelion Ltd, H1 2012 34
Cubist Pharmaceuticals, Inc., H1 2012 35
Mitsubishi Tanabe Pharma Corporation, H1 2012 36
ViroPharma Incorporated, H1 2012 37
Progenics Pharmaceuticals, Inc., H1 2012 38
Avexa Limited, H1 2012 39
Optimer Pharmaceuticals, Inc., H1 2012 40
Paratek Pharmaceuticals, Inc., H1 2012 41
Intercell AG, H1 2012 42
AVANIR Pharmaceuticals, H1 2012 43
Oragenics, Inc., H1 2012 44
XOMA Ltd., H1 2012 45
Immuron Limited, H1 2012 46
Lipoxen PLC, H1 2012 47
Green Cross Corporation, H1 2012 48
LG Life Sciences, Ltd, H1 2012 49
Panacea Biotec Limited, H1 2012 50
Summit Corporation plc, H1 2012 51
PolyMedix, Inc., H1 2012 52
e-Therapeutics plc, H1 2012 53
ActogeniX NV, H1 2012 54
November acta Biosystems Limited, H1 2012 55
Osel Inc., H1 2012 56
iBio, Inc., H1 2012 57
DynPort Vaccine Firms LLC, H1 2012 58
Molecular Targeting Technologies, Inc., H1 2012 59
Assessment by Monotherapy Products, H1 2012 60
Assessment by Combination Products, H1 2012 61
Assessment by Stage and Route of Administration, H1 2012 63
Assessment by Molecule Type, H1 2012 65
Clostridium Infections Therapeutics – Drug Profile Updates 138
Clostridium Infections Therapeutics – Discontinued Products 149
Clostridium Infections Therapeutics – Dormant Products 150
Clostridium Infections Therapeutics – Dormant Products (Contd..1) 151

List of Figures

Number of Products under Development for Clostridium Infections, H1 2012 13
Products under Development for Clostridium Infections – Comparative Analysis, H1 2012 14
Products under Development by Firms, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 19
Late Stage Products, H1 2012 20
Mid Clinical Stage Products, H1 2012 21
Early Clinical Stage Products, H1 2012 22
Discovery and Pre-Clinical Stage Products, H1 2012 23
Assessment by Monotherapy Products, H1 2012 60
Assessment by Combination Products, H1 2012 61
Assessment by Route of Administration, H1 2012 62
Assessment by Stage and Route of Administration, H1 2012 63
Assessment by Molecule Type, H1 2012 64
Assessment by Stage and Molecule Type, H1 2012 65

Infectious Disease in World

Kosovo Pertussis, Total, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Fiji Pertussis, Total, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Fiji, World

Cote D`ivoire Pertussis, Total, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Micronesia( Federated States Of) Pertussis, 0-4 Yrs, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Iraq Pertussis, 0-4 Yrs, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Iraq, World

Pathology in World

Palau Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Iraq Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Iraq, World

Cote D`ivoire Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Congo-brazzaville Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Mali Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Mali, World